Cytodyn Inc (CYDY)

[CTMedic]

Jdf,

As a reminder, the process of scientific advancement is incremental.

To a degree you are correct that “clinical trials have failed.”

Primary endpoint was not met in CD10, rather the more important reduction of SAEs and NEWS2 scores, as opposed to the subjective symptom assessment unfortunately chosen as primary endpoint.

CD12 was not well managed. Age assortment not ensured and essentially two phase 2 trials - severe and critical - rather than a phase 3.

That being said, the science and evidence of leronlimab is unassailable. Rather “lerosaline”, I prefer lerotonic, as we know there are fewer AE and SAEs with its use in Covid than with placebo/saline.

I share your concerns that Cytodyn management may have yet developed the ability to bring leronlimab over the finish line. As Covid rages, leronlimab will continue to garner attention, and not just on Investorshub and social media.

Patience.